to page content
to site navigation
The Foundation's primary site.
Global news, events, and resources.
The national learning program for entrepreneurs.
A new approach to developing the next generation of high-growth firms.
Access to university research and innovation.
The Kauffman Foundation's charter school serving Kansas City.
Encouraging the aspirations of young people.
The platform for business plan competitions.
College preparation and access for urban youth in Kansas City.
A guide to Kauffman Foundation and partner resources, for aspiring entrepreneurs.
News and announcements from the Foundation.
From our vice president of Entrepreneurship.
From our vice president of Advancing Innovation.
News from Global Entrepreneurship Week
News about this education program for entrepreneurs.
Tweets for the eMed Community at Entrepreneurship.org
News from the Kauffman Labs program.
From our business plan competition service.
Contribute to the community seeking to improve entrepreneurship and innovation measurement.
A look at entrepreneurship from the Kauffman Foundation's Thom Ruhe.
Tracks research and policies that are accelerating economic growth and changing the world.
Brings to light various policies and initiatives to advance innovation and drive economic growth.
A selection of our videos
Take our video and audio with you.
Explore many of our publications.
Join the discussion on our LinkedIn site.
Join us on Google's social service.
The Resource Center has all the info you'll need From content to user feedback, the resource center has the information you need for every level of the entrepreneurial process.
Life science entrepreneurs at the Life Science Ventures Summit are set to gain valuable knowledge this weekend from those in the know. Read more about this event for life science entrepreneurs.
Dividing up equity is one of the issues that co-founders face. Read more for guidance on how to split equity among founding partners.
Thoughts on entrepreneurship in the life sciences and digital health from the Kauffman Life Science Ventures Summit are the featured topic of this Storify piece.
Collaboration might just be the key to moving healthcare innovation forward, and a Kauffman Foundation demonstration project is putting this idea to the test. Read more about this project with early-stage innovators.
Advice for life science entrepreneurs goes beyond the dollar value that could be placed on it. Watch this collection of videos with insights on a variety of topics of interest to life science entrepreneurs.
Physician turned venture capitalist Drew Senyei sees education as society's great equalizer.
By 2015 there will be 500 million people under age 30 in China--roughly the population of the entire European Union. And they aren't idolizing Lei Feng, a devoted follower of Mao. They are looking to figures such as Bill Gates and Michael Dell, says Ge Dingkun, a professor of entrepreneurship at China Europe International Business School in Shanghai.
Young people, barely a generation removed from Chairman Mao's strict communism, are embracing entrepreneurship. The incomes of twenty-somethings in China grew 34% in the past three years, the largest growth of any age group, according to a survey by Credit Suisse. While large industries in China--such as banking, steel, telecommunications and electricity generation--are still essentially state-owned, a growing chunk of new wealth being created comes from the hard work and vision of scrappy upstarts.
Peter A. Seligmann is one of today's most dynamic leaders in the global conservation movement, where he has brought innovation and action to the forefront of biodiversity protection for more than 25 years. In 1987, he co-founded Conservation International, and as Chairman and CEO he has positioned CI at the cutting edge of conservation, creating lasting solutions to biodiversity and sustainable development challenges. Seligmann holds a masters degree from Yale University's School of Forestry and Environmental Science and an honorary Doctorate in Science from Michigan State University. In 2001, he was awarded the Order of the Golden Ark from the Netherlands. Seligmann serves on the board of the Wild Salmon Center in Portland, Oregon, and the Mayor's Environmental Council in Washington, D.C. He also serves on several corporate boards, as well as on the advisory councils of the Jackson Hole Land Trust, Ecotrust and other not-for-profit organizations, including the Japanese Keidanren's Nature Conservation Fund. In 2000, President Clinton named him a member of the Enterprise for the Americas Board. Seligmann's work has been featured by ABC's "Nightline," CNN and Fortune Magazine. A strong advocate of building partnerships, Seligmann has forged groundbreaking joint projects between the environmental community and other sectors, including government and industry. In 1998, CI established the Center for Applied Biodiversity Science, and in 2001, the Center for Environmental Leadership in Business. In 2000, CI launched the Critical Ecosystem Partnership Fund in collaboration with the World Bank and the MacArthur Foundation. Under Seligmann's leadership, CI has pioneered conservation tools that are economically sound, scientifically based and culturally sensitive. He has guided CI to become a major international conservation leader, with field offices in more than 30 countries, and major influences
Beth joined Kleiner Perkins Caufield & Byers in May 2005 to work in life sciences. For the past 20 years, she has focused her career on introducing new innovative treatments for AIDS, arthritis, asthma, cancer, psoriasis, cardiovascular, metabolic, neurological and renal disorders. Seidenberg has introduced 10 innovative products to market and achieved over 40 regulatory approvals, including new indications and formulations, worldwide. These products have been successfully commercialized and provided benefits to millions of patients with grievous illnesses, and they have generated several billion dollars of revenue. Prior to joining KPCB, Beth was Senior Vice President, Global Development, and Chief Medical Officer at Amgen, Inc., the world's largest biotechnology company. During Beth's three years there, her responsibilities included all stages of clinical research, regulatory affairs, safety, health economics/reimbursement and medical affairs. During her tenure, five innovative products were approved for commercial use. Prior to joining Amgen, Beth was a senior executive in research and development at Bristol-Myers Squibb Company and Merck & Co., Inc. She began her career in basic and clinical research at the National Institutes of Health specializing in immunology and infectious diseases. Beth received her BS from Barnard College magna cum laude, Phi Beta Kappa; and her medical degree from the University Of Miami School Of Medicine, alpha omega alpha. Her post-graduate training was completed at Johns Hopkins, George Washington School of Medicine and the National Institutes of Health. She is a member of the Johns Hopkins Bloomberg School of Public Health Advisory Board and Barnard College Science Advisory Board.
Beth Seidenberg, partner at venture firm Kleiner Perkins Caufield & Byers, speaks at length about KPCB's current areas of interest, and its litmus test for projects worth supporting. Seidenberg also offers a case study of a life sciences firm moving from research lab toward market.
Want to get connected? Sign up to receive regular news, polls and updates from The Kauffman Foundation.
